Claims for Patent: 10,596,178

Summary for Patent: 10,596,178

Title:	Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
Abstract:	The present invention is related to tablets comprising of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,-2-b][1,2,4]triazin- -2-yl]benzamide, processes for the production thereof, and uses in the treatment of certain cancers.
Inventor(s):	Goncalves; Elisabete (Basel, CH), Tauchmann; Christin (Sankt Florianweg, GE), Yen; Shau-Fong (Basel, CH), Vippagunta; Sudha (Morris Plains, NJ), Zong; Zhixin (Franklin Park, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	16/134,162
Patent Claims:	1. A tablet comprising 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-- 2-yl]benzamide, or a pharmaceutically acceptable salt thereof, wherein the tablet comprises: (a) an intragranular phase comprising, by weight, about: 23.54% of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-- 2-yl]benzamide dihydrochloric acid salt, 20% of mannitol, 20.26% of microcrystalline cellulose, 0.2% of sodium dodecyl sulfate, 5% of polyvinylpolypyrrolidone, and 4% of polyvinylpyrrolidone; and (b) an extragranular phase comprising, by weight, about: 20.75% of microcrystalline cellulose, 0.5% of colloidal silicon dioxide, 5% of polyvinylpolypyrrolidone, and 0.75% of magnesium stearate; wherein the percentages given for the respective ingredients are relative to the total weight of the tablet.